GO:1990262 anti-Mullerian hormone receptor signaling pathway: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1990262 describes the signaling cascade triggered when anti-Mullerian hormone (AMH) binds its receptor on the cell surface, leading to regulation of downstream transcription.
• The pathway is a sex-specific member of the TGF-beta superfamily and is essential for male sexual differentiation and gonadal development.
• Upon ligand binding, AMH receptor type II (AMHR2) recruits and phosphorylates type I receptors, which then activate SMAD transcriptional regulators.
• Dysregulation of AMH signaling is implicated in polycystic ovary syndrome (PCOS), lung cancer, and other endocrine and oncological conditions.
• Key genes in this pathway include AMH, AMHR2, and downstream SMAD effectors, which are frequent targets for CRISPR knockout, knock-in, and point-mutation studies.
• Research tools such as RNA-seq, phosphoproteomics, and CRISPR screens are used to dissect AMH signaling in reproductive biology and cancer.
Description
The anti-Mullerian hormone receptor signaling pathway (GO:1990262) is a biological process that begins with the binding of anti-Mullerian hormone (AMH) to its specific receptor on the surface of target cells and culminates in the regulation of downstream cellular responses, including transcription. AMH, also known as Mullerian inhibiting substance, is a member of the transforming growth factor-beta (TGF-beta) superfamily and plays a critical role in sexual differentiation and gonadal function. This pathway is particularly notable for its sex-specific roles, being essential for the regression of Mullerian ducts in male embryos and for the regulation of follicular development in females. Researchers study GO:1990262 to understand fundamental mechanisms of development, endocrine regulation, and disease pathogenesis, as its dysregulation has been linked to conditions such as polycystic ovary syndrome (PCOS) and various cancers. The pathway's unique signaling components, including the AMH type II receptor (AMHR2) and SMAD proteins, make it a compelling target for genetic and pharmacological interventions.
anti-Mullerian hormone receptor signaling pathway At A Glance
| GO ID | GO:1990262 |
|---|---|
| GO term | anti-Mullerian hormone receptor signaling pathway |
| Ontology | biological_process |
| Synonym | anti-Mullerian hormone signaling pathway |
| Major function | Transduces AMH signals from the cell surface to the nucleus, regulating gene expression involved in sexual differentiation, gonadal development, and cellular proliferation. |
| Key receptors | AMHR2 (type II receptor) and type I receptors such as ALK2, ALK3, or ALK6. |
| Downstream effectors | SMAD1, SMAD5, SMAD8 (receptor-regulated SMADs) and SMAD4 (common mediator). |
| Ligand | Anti-Mullerian hormone (AMH), a TGF-beta family member. |
| Associated diseases | Polycystic ovary syndrome, lung cancer, and other endocrine and reproductive disorders. |
What Is GO:1990262?
GO:1990262, the anti-Mullerian hormone receptor signaling pathway, is defined as the series of molecular signals initiated by the binding of anti-Mullerian hormone to its receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process, such as transcription. Upon ligand binding, the receptor forms a complex consisting of two type II and two type I transmembrane serine/threonine kinases. Type II receptors phosphorylate and activate type I receptors, which autophosphorylate and then bind and activate SMAD transcriptional regulators.
Why Is anti-Mullerian hormone receptor signaling pathway Important in Cell Biology?
Understanding GO:1990262 is crucial because AMH signaling is a key regulator of reproductive development and function, and its perturbation is associated with a range of human diseases. In males, AMH signaling drives the regression of Mullerian ducts, a process essential for normal male sexual differentiation. In females, it regulates follicular recruitment and steroidogenesis, and altered AMH levels are a hallmark of PCOS. Moreover, AMH signaling has been implicated in cancer biology, where it can influence epithelial plasticity, chemoresistance, and cell proliferation in lung cancer and other malignancies. Thus, dissecting this pathway offers insights into developmental biology, endocrinology, and oncology, and may reveal therapeutic targets.
• Essential for male sexual differentiation by mediating Mullerian duct regression.
• Regulates ovarian follicular development and function, with implications for female fertility.
• Dysregulation is linked to polycystic ovary syndrome (PCOS), a common endocrine disorder.
• Plays a role in cancer biology, including lung cancer proliferation and chemoresistance.
• Serves as a model for understanding TGF-beta superfamily signaling specificity.
• Provides potential therapeutic targets for reproductive and oncological diseases.
• Involves unique receptor complexes that can be studied with CRISPR-based genetic tools.
• AMH is used clinically as a biomarker for ovarian reserve, reflecting pathway activity.
• Cross-talk with other signaling pathways (e.g., BMP, TGF-beta) modulates cellular outcomes.
• Animal models and cell lines with pathway mutations are valuable for drug discovery.
What Happens During anti-Mullerian hormone receptor signaling pathway?
Ligand Binding and Receptor Complex Formation
In simple terms: AMH binds to its receptor on the cell surface, bringing together two types of receptor proteins.
The pathway is initiated when anti-Mullerian hormone (AMH) binds to the anti-Mullerian hormone type II receptor (AMHR2), a transmembrane serine/threonine kinase. This binding induces the formation of a heteromeric complex consisting of two type II receptors and two type I receptors (such as ALK2, ALK3, or ALK6). The type II receptor is constitutively active and phosphorylates the type I receptor upon complex formation.
Type I Receptor Activation and SMAD Phosphorylation
In simple terms: The type II receptor activates the type I receptor, which then turns on SMAD proteins inside the cell.
Once phosphorylated by the type II receptor, the type I receptor undergoes autophosphorylation and becomes active. The activated type I receptor then phosphorylates receptor-regulated SMADs (R-SMADs), specifically SMAD1, SMAD5, and SMAD8, at their C-terminal SSXS motifs. This phosphorylation triggers a conformational change that allows R-SMADs to dissociate from the receptor complex.
SMAD Complex Formation and Nuclear Translocation
In simple terms: Activated SMADs pair with a common partner and move into the nucleus to control gene expression.
Phosphorylated R-SMADs form heteromeric complexes with the common mediator SMAD4. These complexes then translocate to the nucleus, where they bind to specific DNA sequences in target gene promoters and interact with various transcription factors to regulate gene expression. This transcriptional regulation mediates the diverse biological effects of AMH signaling.
Regulation of Downstream Cellular Processes
In simple terms: The signal ultimately changes how cells behave, such as by altering growth, differentiation, or death.
The nuclear SMAD complexes modulate the transcription of target genes that control cell proliferation, differentiation, apoptosis, and extracellular matrix remodeling. In the developing male embryo, this leads to regression of the Mullerian ducts. In postnatal females, it regulates follicular development and steroidogenesis. In cancer cells, AMH signaling can influence epithelial plasticity and chemoresistance.
Key Genes Involved in GO:1990262 anti-Mullerian hormone receptor signaling pathway
The following genes and proteins are central to the anti-Mullerian hormone receptor signaling pathway, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| AMH | Encodes the ligand anti-Mullerian hormone, which initiates the pathway by binding to AMHR2. | Target for understanding ligand availability and mutations affecting hormone function. |
| AMHR2 | Encodes the type II receptor that binds AMH and phosphorylates type I receptors. | Frequently studied in reproductive disorders and cancers; knockout models reveal pathway necessity. |
| ALK2 (ACVR1) | Type I receptor that can be activated by AMHR2 to propagate signaling. | Potential target for modulating pathway activity in disease. |
| ALK3 (BMPR1A) | Type I receptor involved in AMH signaling in certain contexts. | Studied for its role in tissue-specific responses. |
| ALK6 (BMPR1B) | Type I receptor that mediates AMH signaling in gonadal tissues. | Relevant for reproductive biology and cancer. |
| SMAD1 | Receptor-regulated SMAD that is phosphorylated and translocates to the nucleus. | Key effector for transcriptional responses; knockout affects development. |
| SMAD5 | R-SMAD involved in AMH signal transduction. | Target for studying pathway specificity. |
| SMAD8 (SMAD9) | R-SMAD that participates in AMH signaling. | Less studied but contributes to pathway diversity. |
| SMAD4 | Common mediator SMAD that forms complexes with R-SMADs. | Essential for nuclear translocation and gene regulation; knockout is lethal. |
| SOX9 | Transcription factor that cooperates with AMH signaling in male sexual differentiation. | Studied for its role in gonadal development. |
| WT1 | Transcription factor regulating AMH expression and gonadal development. | Implicated in Wilms tumor and reproductive disorders. |
| GATA4 | Transcription factor that regulates AMH gene expression. | Important for gonadal differentiation. |
| SF1 (NR5A1) | Nuclear receptor that controls AMH expression and steroidogenesis. | Mutations cause adrenal and gonadal disorders. |
| FOXL2 | Transcription factor that represses AMH in females. | Critical for ovarian maintenance. |
| BMPR2 | Type II receptor that can modulate AMH signaling. | Studied for cross-talk with BMP pathway. |
| TGFBR1 | Type I receptor with potential roles in AMH signaling. | Target for understanding pathway cross-talk. |
| SMAD2/3 | Inhibitory SMADs that can antagonize AMH signaling. | Studied for negative regulation of the pathway. |
| SMAD6/7 | Inhibitory SMADs that feedback to dampen signaling. | Important for pathway termination and homeostasis. |
How Is anti-Mullerian hormone receptor signaling pathway Regulated?
The anti-Mullerian hormone receptor signaling pathway is tightly regulated at multiple levels. Extracellularly, the availability of AMH ligand is controlled by transcriptional regulation of the AMH gene by transcription factors such as SOX9, SF1, WT1, and GATA4 in males, and its repression by FOXL2 in females. Intracellularly, inhibitory SMADs (SMAD6 and SMAD7) can block receptor-mediated phosphorylation of R-SMADs, providing negative feedback. Additionally, cross-talk with other signaling pathways, such as BMP and TGF-beta, can modulate the intensity and duration of AMH signaling. Post-translational modifications and receptor trafficking also influence pathway activity.
anti-Mullerian hormone receptor signaling pathway and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| AMH | PCOS, ovarian insufficiency | Amh knockout mouse; overexpression in granulosa cell lines. |
| AMHR2 | Lung cancer, PCOS | AMHR2 knockout NSCLC cell lines; xenograft models. |
| SMAD1/5/8 | Developmental disorders, cancer | CRISPR knockout in cell lines; phospho-SMAD assays. |
| SMAD4 | Cancer, developmental defects | Conditional knockout mouse models; cell lines. |
| FOXL2 | Ovarian failure, PCOS | Foxl2 knockout mouse; granulosa cell models. |
Polycystic Ovary Syndrome (PCOS)
PCOS is a common endocrine disorder characterized by hyperandrogenism, ovulatory dysfunction, and polycystic ovaries. Elevated AMH levels are a hallmark of PCOS, and recent studies have shown that targeting AMH signaling during minipuberty or adulthood can prevent and correct PCOS in mouse models. AMH signaling dysregulation contributes to follicular arrest and steroidogenic abnormalities, making it a therapeutic target. Research into the molecular regulation of AMH in PCOS is ongoing, with emerging strategies aimed at modulating the pathway.
Lung Cancer
AMH and its type II receptor (AMHR2) are expressed in non-small cell lung cancer (NSCLC), where AMH signaling can regulate cancer cell proliferation. Activation of AMH/AMHR2 signaling has been shown to influence epithelial plasticity and chemoresistance, suggesting that targeting this pathway could overcome treatment resistance. Studies using NSCLC cell lines and xenograft models have demonstrated that modulation of AMH signaling affects tumor growth and response to chemotherapy.
Other Cancers and Endocrine Disorders
AMH signaling has been implicated in other cancers, including ovarian and breast cancers, where it may influence cell proliferation and differentiation. In endocrine contexts, AMH is a key biomarker for ovarian reserve and is used clinically to assess reproductive function. Dysregulation of the pathway can also contribute to disorders of sex development and gonadal dysgenesis.
From anti-Mullerian hormone receptor signaling pathway-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does AMH signaling drive PCOS pathogenesis? | Amh or Amhr2 knockout mouse; minipuberty intervention models. |
| How does AMHR2 affect lung cancer proliferation? | AMHR2 knockout NSCLC cell lines; overexpression and xenografts. |
| What is the role of SMAD4 in AMH signaling? | SMAD4 conditional knockout in gonadal or cancer cells. |
| Can point mutations in AMHR2 alter ligand binding? | CRISPR knock-in of patient-derived mutations in cell lines. |
| How does FOXL2 repress AMH transcription? | FOXL2 knockout or overexpression in granulosa cells. |
| What are the downstream targets of AMH signaling? | RNA-seq and ChIP-seq in cells with tagged SMADs. |
How to Study the anti-Mullerian hormone receptor signaling pathway Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Global gene expression changes | Identify AMH-regulated transcripts in gonadal or cancer cells. |
| ChIP-seq | SMAD binding sites on DNA | Map direct transcriptional targets of AMH signaling. |
| Phosphoproteomics | Phosphorylation events | Monitor receptor and SMAD activation. |
| Western blot | Protein expression and phosphorylation | Validate pathway activation in cell lines. |
| CRISPR screen | Gene essentiality or modifiers | Discover regulators of AMH signaling. |
| Luciferase reporter | Transcriptional activity | Measure SMAD-dependent promoter activity. |
| Immunofluorescence | Protein localization | Visualize SMAD nuclear translocation. |
| Flow cytometry | Cell proliferation or apoptosis | Assess functional outcomes of AMH signaling. |
Transcriptomic and Epigenomic Profiling
RNA-seq and ChIP-seq are used to identify genes and regulatory elements controlled by AMH signaling. For example, RNA-seq of cells treated with AMH or with SMAD knockdowns reveals transcriptional targets. ChIP-seq for SMAD1/5/8 can map binding sites across the genome, providing insights into direct targets.
Phosphoproteomics and Signaling Assays
Phosphoproteomics and Western blotting with phospho-specific antibodies are employed to monitor activation of the pathway, such as phosphorylation of type I receptors and SMADs. These methods are critical for determining the kinetics and intensity of signaling in response to AMH.
CRISPR-Based Genetic Screens
Genome-wide CRISPR knockout or activation screens can identify modifiers of AMH signaling. For instance, screens in cancer cell lines have uncovered genes that modulate sensitivity to AMH-induced growth inhibition. Such screens are powerful for discovering novel pathway components and therapeutic targets.
Imaging and Reporter Assays
Fluorescent reporter assays (e.g., SMAD-responsive luciferase) and live-cell imaging of tagged receptors or SMADs allow real-time visualization of pathway activation and subcellular localization. These techniques are valuable for studying dynamic signaling events in living cells.
How CRISPR Can Be Used to Study GO:1990262 anti-Mullerian hormone receptor signaling pathway
Knockout
CRISPR knockout of AMH, AMHR2, or SMAD genes is used to ablate pathway components and study their necessity in developmental and disease models. For example, AMHR2 knockout in lung cancer cell lines has been used to demonstrate its role in proliferation. In mice, knockout of Amh or Amhr2 leads to retention of Mullerian ducts and gonadal abnormalities.
Point Mutation
CRISPR-mediated point mutations can model patient-derived variants in AMHR2 or SMAD genes to assess their impact on receptor function, ligand binding, or transcriptional activity. Such models are valuable for understanding the molecular basis of diseases like PCOS or cancer.
Knock-in
Knock-in of tagged versions of AMHR2 or SMAD proteins (e.g., GFP or HA tags) allows for real-time tracking and biochemical purification of pathway components. This approach facilitates the study of protein interactions and dynamics in live cells.
Overexpression
Overexpression of AMH or constitutively active receptors can amplify signaling to study downstream effects or to model diseases characterized by pathway overactivation. In PCOS models, overexpression of AMH in minipuberty has been used to induce PCOS-like phenotypes.
How EDITGENE Supports anti-Mullerian hormone receptor signaling pathway Research
Researchers studying anti-Mullerian hormone receptor signaling pathway-related genes often need to determine whether a candidate gene is causally involved in pathway regulation, disease pathogenesis, or therapeutic response. EDITGENE provides comprehensive CRISPR-based services to enable such investigations with precision and efficiency.
Contact EDITGENE today to design your custom CRISPR model for anti-Mullerian hormone receptor signaling pathway research.
Frequently Asked Questions About anti-Mullerian hormone receptor signaling pathway
What is the anti-Mullerian hormone receptor signaling pathway?
It is a biological process (GO:1990262) where anti-Mullerian hormone binds its receptor, triggering a signaling cascade that regulates gene expression, primarily through SMAD proteins.
What genes are involved in anti-Mullerian hormone receptor signaling?
Key genes include AMH, AMHR2, type I receptors (e.g., ALK2, ALK3, ALK6), and SMADs (SMAD1, SMAD5, SMAD8, SMAD4).
How does AMH signaling work?
AMH binds AMHR2, which phosphorylates type I receptors; these activate SMADs that translocate to the nucleus to control transcription.
What diseases are associated with AMH signaling?
Dysregulation is linked to polycystic ovary syndrome (PCOS), lung cancer, and other reproductive and endocrine disorders.
What is the role of AMH in PCOS?
Elevated AMH levels contribute to PCOS pathogenesis, and targeting AMH signaling can prevent or correct PCOS in mouse models.
How is AMH signaling studied in the lab?
Common methods include CRISPR knockout, RNA-seq, phosphoproteomics, and reporter assays.
What are the downstream effectors of AMH signaling?
The main effectors are SMAD1, SMAD5, SMAD8, and SMAD4, which regulate transcription.
Can AMH signaling be targeted therapeutically?
Yes, it is a potential target for PCOS and certain cancers, with ongoing research into inhibitors and modulators.
What is the difference between AMH and AMHR2?
AMH is the ligand (hormone), while AMHR2 is the type II receptor that binds AMH and initiates signaling.
What model organisms are used to study AMH signaling?
Mouse models, particularly Amh and Amhr2 knockouts, are widely used, along with cell lines such as NSCLC and granulosa cells.
Conclusion
The anti-Mullerian hormone receptor signaling pathway (GO:1990262) is a critical biological process that governs sexual differentiation, gonadal function, and cellular responses in health and disease. Its dysregulation is implicated in PCOS, lung cancer, and other disorders, making it a focal point for both basic and translational research. Advances in CRISPR-based genetic tools and high-throughput omics are accelerating our understanding of this pathway and opening new avenues for therapeutic intervention.
References
- 1. Cotellessa L et al.. 2025. Preventing and correcting polycystic ovary syndrome by targeting anti-Müllerian hormone signaling in minipuberty and adulthood in mice.. Cell Metab 37(6):1260-1276.e8 PMID: 40220763
- 2. Koinuma Y et al.. 2024. Anti-Müllerian hormone type II receptor protein expression in non-small cell lung cancer and the effect of AMH/AMHR2 signaling on cancer cell proliferation.. Thorac Cancer 15(29):2090-2099 PMID: 39230026
- 3. Josso N et al.. 2001. Anti-Müllerian hormone and its receptors.. Mol Cell Endocrinol 179(1-2):25-32 PMID: 11420127
- 4. Howard JA et al.. 2022. Molecular Mechanisms of AMH Signaling.. Front Endocrinol (Lausanne) 13:927824 PMID: 35813657
- 5. Josso N et al.. 2003. Transduction pathway of anti-Müllerian hormone, a sex-specific member of the TGF-beta family.. Trends Endocrinol Metab 14(2):91-7 PMID: 12591180
- 6. Ke Y et al.. 2025. Anti-Müllerian hormone in PCOS: Molecular regulation and emerging therapeutic strategies.. Biomol Biomed 26(2):173-185 PMID: 40257231
- 7. Gowkielewicz M et al.. 2024. Anti-Müllerian hormone: biology and role in endocrinology and cancers.. Front Endocrinol (Lausanne) 15:1468364 PMID: 39351532
- 8. Beck TN et al.. 2016. Anti-Müllerian Hormone Signaling Regulates Epithelial Plasticity and Chemoresistance in Lung Cancer.. Cell Rep 16(3):657-671 PMID: 27396341
